Abcam, ab249129, Anti-ACADS/SCAD antibody [EPR10861(B)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ACADS/SCAD antibody. Carrier free. Suitable for WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR10861(B),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249129 is the carrier-free version of
ab154823
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ACADS protein also known as short-chain acyl-CoA dehydrogenase (SCAD) is an enzyme that plays a mechanical role in the mitochondrial fatty acid beta-oxidation process. It catalyzes the dehydrogenation of acyl-CoA substrates specifically short-chain fatty acids. The molecular mass of the ACADS protein is approximately 44 kDa. Expression of the ACADS protein occurs in the mitochondria of various tissues especially in liver and muscle tissues where fatty acid metabolism is active.
Biological function summary
The function of ACADS involves the conversion of fatty acids into acetyl-CoA an essential step in energy production. ACADS operates in concert with other enzymes in the mitochondrial matrix contributing to the beta-oxidation cycle. This enzyme is essential for maintaining energy homeostasis particularly during periods of fasting or increased energy demands. Although ACADS is not a component of a larger enzyme complex it works closely with other dehydrogenases that metabolize different chain lengths of fatty acids.
Pathways
The ACADS enzyme is critically involved in the fatty acid beta-oxidation pathway. This pathway is vital for energy production especially in cardiac and skeletal muscles. ACADS is functionally related to other enzymes such as MCAD (medium-chain acyl-CoA dehydrogenase) and VLCAD (very long-chain acyl-CoA dehydrogenase) through the sequential processing of fatty acids of varying chain lengths. Proper functioning of the beta-oxidation pathway ensures that fatty acids are systematically broken down to meet the body’s energetic needs.
Defects in ACADS are associated with metabolic disorders namely short-chain acyl-CoA dehydrogenase deficiency (SCADD). This condition can result in muscle weakness developmental delay and hypoglycemia. ACADS is also indirectly linked to disorders involving MCAD as both enzymes function within the same metabolic pathway. Accurate diagnosis and management of SCADD rely on understanding the role of ACADS and its interactions with interconnected proteins in the metabolic network.